Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.54
NYSE:MRK's Cash-to-Debt is ranked lower than
68% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. NYSE:MRK: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:MRK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 0.74 Max: N/A
Current: 0.54
Equity-to-Asset 0.41
NYSE:MRK's Equity-to-Asset is ranked lower than
79% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:MRK: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:MRK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.45 Max: 0.53
Current: 0.41
0.34
0.53
Interest Coverage 9.22
NYSE:MRK's Interest Coverage is ranked lower than
74% of the 638 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.48 vs. NYSE:MRK: 9.22 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 10.18 Max: 20.13
Current: 9.22
4.14
20.13
Piotroski F-Score: 7
Altman Z-Score: 3.29
Beneish M-Score: -2.66
WACC vs ROIC
7.26%
9.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 16.23
NYSE:MRK's Operating Margin % is ranked higher than
73% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. NYSE:MRK: 16.23 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:MRK' s Operating Margin % Range Over the Past 10 Years
Min: 6.43  Med: 16.53 Max: 21.86
Current: 16.23
6.43
21.86
Net Margin % 10.88
NYSE:MRK's Net Margin % is ranked higher than
67% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. NYSE:MRK: 10.88 )
Ranked among companies with meaningful Net Margin % only.
NYSE:MRK' s Net Margin % Range Over the Past 10 Years
Min: 1.87  Med: 13.05 Max: 47.03
Current: 10.88
1.87
47.03
ROE % 10.30
NYSE:MRK's ROE % is ranked higher than
62% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NYSE:MRK: 10.30 )
Ranked among companies with meaningful ROE % only.
NYSE:MRK' s ROE % Range Over the Past 10 Years
Min: 1.51  Med: 11.48 Max: 42.27
Current: 10.3
1.51
42.27
ROA % 4.47
NYSE:MRK's ROA % is ranked higher than
55% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NYSE:MRK: 4.47 )
Ranked among companies with meaningful ROA % only.
NYSE:MRK' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 5.9 Max: 16.34
Current: 4.47
0.79
16.34
ROC (Joel Greenblatt) % 43.21
NYSE:MRK's ROC (Joel Greenblatt) % is ranked higher than
80% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. NYSE:MRK: 43.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:MRK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.88  Med: 44.45 Max: 105.49
Current: 43.21
10.88
105.49
3-Year Revenue Growth Rate -0.90
NYSE:MRK's 3-Year Revenue Growth Rate is ranked lower than
71% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:MRK: -0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:MRK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.5  Med: 8.4 Max: 22.8
Current: -0.9
-16.5
22.8
3-Year EBITDA Growth Rate -4.50
NYSE:MRK's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. NYSE:MRK: -4.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:MRK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 8.1 Max: 44.8
Current: -4.5
-17.6
44.8
3-Year EPS without NRI Growth Rate -1.40
NYSE:MRK's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. NYSE:MRK: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:MRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: 12.2 Max: 73.8
Current: -1.4
-29.3
73.8
GuruFocus has detected 6 Warning Signs with Merck & Co Inc $NYSE:MRK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:MRK's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:NVSEF, NYSE:PFE, OTCPK:RHHBY, NYSE:SNY, NYSE:ABBV, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHF, NAS:HCM, OTCPK:GWPRF » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, infections, and osteoporosis. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Following the Schering acquisition, close to half of the company's sales are generated in the United States.

Top Ranked Articles about Merck & Co Inc

Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna Vanguard Health Care Fund's largest 1st-quarter trades
Edward Owens has managed the Vanguard Health Care Fund (Trades, Portfolio) since its inception in May 1984. It invests primarily in health care companies. Read more...
Osteoporosis Drug Meets Primary and Secondary Endpoints But researchers observe a higher rate of serious cardiovascular adverse events
Amgen Inc. (NASDAQ:AMGN) informed the stock market through the PRNewswire May 21 about the results of the ARCH clinical trial, Phase 3, with which Evenity (romosozumab) – an investigational monoclonal antibody that increases bone formation – was assessed in postmenopausal women affected with osteoporosis and who have a high risk of fracture. Evenity is aimed to prevent fractures in these patients. Read more...
Howard Marks on the Truth About Investing The value investor discusses the best ways to invest
Howard Marks (Trades, Portfolio) is one of Wall Street’s most astute value investors. He is known in the investment community for his Oaktree memos to clients, which detail investment strategies and insights on the economy. These memos are always highly informative as Marks has an unrivaled view of Wall Street. His Oaktree Capital invests in distressed assets, the very essence of value investing, and in 2008, Oaktree raised $10.9 billion from investors, making it the largest distressed-debt fund in history. Oaktree’s 17 distressed debt funds have achieved annualized returns of 19% per annum after fees for the past 22 years. Read more...
US Market Indexes Higher on Thursday Stocks regain some ground lost due to political concerns
U.S. market indexes regained some of their losses from political worries on Thursday. Read more...
Tweedy Browne Hooks Up Baidu in 1st Quarter Guru adds 3 new positions to portfolio
Tweedy Browne (Trades, Portfolio), an investment partnership owned by managing directors William Browne, John Spears, Thomas Shrager and Robert Wyckoff, invests in companies using a Ben Graham style approach. Tweedy Browne’s investment partnership, recognized by Warren Buffett (Trades, Portfolio) as Graham-Doddsville Superinvestors, added three new positions during the first quarter: Baidu Inc. (NASDAQ:BIDU), Signet Jewelers Ltd. (NYSE:SIG) and Merck & Co. Inc. (NYSE:MRK). Read more...
Nasdaq Closes at 6121, Stocks Mostly Lower The index gains 0.34% for the week
U.S. market indexes were mostly lower on Friday with the Nasdaq gaining to report its fourth consecutive weekly increase. For the day, the Dow Jones Industrial Average closed at 20896.61 for a loss of -22.81 points or -0.11%. The S&P 500 closed at 2390.90 for a loss of -3.54 points or -0.15%. The Nasdaq Composite closed at 6121.23 for a gain of 5.27 points or 0.09%. The VIX Volatility Index was lower for the day at 10.42 with a loss of -0.18 points or -1.70%. Read more...
Kahn Brothers Sells Hologic, Pfizer, Citigroup The guru's largest 1st-quarter transactions
Irving Kahn, along with brothers Alan and Thomas, founded Kahn Brothers (Trades, Portfolio) in 1978. Kahn Brothers employs a bottom-up stock selection approach and invests in undervalued equity securities that are usually out of favor in the market. During the first quarter the guru sold shares in the following stocks: Read more...
US Market Indexes Mostly Lower Nasdaq closes at a new high
U.S. market indexes were mostly lower Tuesday. Read more...
Stocks Lower With Disappointing Earnings From Apple Nasdaq closes at 6072.55
U.S. market indexes were mostly lower on Wednesday. For the day, the Dow Jones Industrial Average closed at 20957.90 for a gain of 8.01 points or 0.04%. The S&P 500 closed at 2388.13 for a loss of -3.04 points or -0.13%. The Nasdaq Composite closed at 6072.55 for a loss of -22.82 points or -0.37%. The VIX Volatility Index was higher at 10.68 with a gain of 0.09 points or 0.85%. Read more...

Ratios

vs
industry
vs
history
PE Ratio 42.01
MRK's PE Ratio is ranked lower than
71% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.96 vs. MRK: 42.01 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 22.05 Max: 138.33
Current: 42.01
6.33
138.33
Forward PE Ratio 17.09
MRK's Forward PE Ratio is ranked higher than
63% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.46 vs. MRK: 17.09 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.01
MRK's PE Ratio without NRI is ranked lower than
71% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.64 vs. MRK: 42.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 22.05 Max: 138.33
Current: 42.01
6.33
138.33
Price-to-Owner-Earnings 83.38
MRK's Price-to-Owner-Earnings is ranked lower than
81% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. MRK: 83.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.35  Med: 16.7 Max: 84.71
Current: 83.38
6.35
84.71
PB Ratio 4.51
MRK's PB Ratio is ranked lower than
71% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. MRK: 4.51 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.21 Max: 7.25
Current: 4.51
1.72
7.25
PS Ratio 4.56
MRK's PS Ratio is ranked lower than
64% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. MRK: 4.56 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.33 Max: 5.48
Current: 4.56
2.01
5.48
Price-to-Free-Cash-Flow 26.75
MRK's Price-to-Free-Cash-Flow is ranked lower than
53% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. MRK: 26.75 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.5 Max: 88.07
Current: 26.75
7.88
88.07
Price-to-Operating-Cash-Flow 21.47
MRK's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. MRK: 21.47 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 14.09 Max: 35.61
Current: 21.47
6.68
35.61
EV-to-EBIT 33.57
MRK's EV-to-EBIT is ranked lower than
73% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.48 vs. MRK: 33.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 17.55 Max: 52.5
Current: 33.57
4.9
52.5
EV-to-EBITDA 17.82
MRK's EV-to-EBITDA is ranked lower than
51% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.55 vs. MRK: 17.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.4 Max: 20.4
Current: 17.82
4.2
20.4
Shiller PE Ratio 29.25
MRK's Shiller PE Ratio is ranked higher than
64% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.91 vs. MRK: 29.25 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.27  Med: 16.94 Max: 29.72
Current: 29.25
8.27
29.72
Current Ratio 1.59
MRK's Current Ratio is ranked lower than
70% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 1.59 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.51 Max: 3.7
Current: 1.59
0.97
3.7
Quick Ratio 1.33
MRK's Quick Ratio is ranked lower than
64% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. MRK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.19 Max: 3.44
Current: 1.33
0.69
3.44
Days Inventory 146.73
MRK's Days Inventory is ranked lower than
65% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. MRK: 146.73 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 108.49  Med: 130.49 Max: 205.16
Current: 146.73
108.49
205.16
Days Sales Outstanding 64.59
MRK's Days Sales Outstanding is ranked higher than
59% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. MRK: 64.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 59.4 Max: 87.87
Current: 64.59
44.5
87.87
Days Payable 68.00
MRK's Days Payable is ranked lower than
52% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. MRK: 68.00 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 37.12  Med: 47.38 Max: 90.81
Current: 68
37.12
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.85
MRK's Dividend Yield % is ranked higher than
80% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. MRK: 2.85 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.51  Med: 3.63 Max: 6.68
Current: 2.85
2.51
6.68
Dividend Payout Ratio 1.18
MRK's Dividend Payout Ratio is ranked higher than
55% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. MRK: 1.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.85 Max: 5.43
Current: 1.18
0.27
5.43
3-Year Dividend Growth Rate 2.30
MRK's 3-Year Dividend Growth Rate is ranked lower than
62% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. MRK: 2.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 31
Current: 2.3
0
31
Forward Dividend Yield % 2.85
MRK's Forward Dividend Yield % is ranked higher than
75% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.71 vs. MRK: 2.85 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.32
MRK's 5-Year Yield-on-Cost % is ranked higher than
71% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. MRK: 3.32 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.92  Med: 4.23 Max: 7.78
Current: 3.32
2.92
7.78
3-Year Average Share Buyback Ratio 2.10
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. MRK: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.1 Max: 2.8
Current: 2.1
-13
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 38.92
MRK's Price-to-Tangible-Book is ranked lower than
96% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. MRK: 38.92 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MRK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 10.88 Max: 3112.5
Current: 38.92
3.19
3112.5
Price-to-Intrinsic-Value-Projected-FCF 1.56
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. MRK: 1.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.48
Current: 1.56
0.75
3.48
Price-to-Median-PS-Value 1.37
MRK's Price-to-Median-PS-Value is ranked lower than
68% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. MRK: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.2 Max: 2.14
Current: 1.37
0.64
2.14
Price-to-Graham-Number 8.52
MRK's Price-to-Graham-Number is ranked lower than
94% of the 484 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. MRK: 8.52 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MRK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.25 Max: 31.92
Current: 8.52
1.09
31.92
Earnings Yield (Greenblatt) % 2.98
MRK's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. MRK: 2.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.7 Max: 20.6
Current: 2.98
1.9
20.6
Forward Rate of Return (Yacktman) % 2.88
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. MRK: 2.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.7  Med: 7.8 Max: 20.4
Current: 2.88
-5.7
20.4

More Statistics

Revenue (TTM) (Mil) $39,929.00
EPS (TTM) $ 1.56
Beta0.97
Short Percentage of Float0.77%
52-Week Range $55.10 - 66.80
Shares Outstanding (Mil)2,735.16

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39,935 40,850 42,678
EPS ($) 3.84 4.21 4.73
EPS without NRI ($) 3.84 4.21 4.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.21%
Dividends per Share ($) 1.86 1.94 1.97
» More Articles for MRK

Headlines

Articles On GuruFocus.com
VBI Vaccines Just Took a Major Step Forward in Its HBV Program Jun 21 2017 
DarioHealth: Disruption Is Valuable Jun 07 2017 
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Jun 07 2017 
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna May 23 2017 
Osteoporosis Drug Meets Primary and Secondary Endpoints May 23 2017 
Howard Marks on the Truth About Investing May 19 2017 
US Market Indexes Higher on Thursday May 18 2017 
Tweedy Browne Hooks Up Baidu in 1st Quarter May 17 2017 
Nasdaq Closes at 6121, Stocks Mostly Lower May 12 2017 
Kahn Brothers Sells Hologic, Pfizer, Citigroup May 11 2017 

More From Other Websites
[$$] Cyberattacks Hit Major Companies Across Globe Jun 27 2017
Cyber attack sweeps globe, researchers see 'WannaCry' link Jun 27 2017
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc. Jun 27 2017
[$$] Merck Cholesterol Drug Could Help Unlock Value Jun 27 2017
Everything to Know About Today’s Worldwide Ransomware Attack Jun 27 2017
Merck says new type of cholesterol drug worked in big study Jun 27 2017
Mondelez, other companies experiencing global computer ou... Jun 27 2017
What to do if involved in a cyber attack: Former FBI spec... Jun 27 2017
Pfizer’s Valuation as of June 22, 2017 Jun 27 2017
Shocker: Merck Cholesterol Drug Yields Benefit Where Rivals Failed Jun 27 2017
Does Merck's Rally Have Legs? Jun 27 2017
Merck's cholesterol drug clears main goal in late-stage study Jun 27 2017
Merck Provides Update on REVEAL Outcomes Study of Anacetrapib Jun 27 2017
After health care gains eight percent in one quarter Jun 26 2017
The 3 Top Stocks for Your IRA in June Jun 26 2017
Better Buy: Merck & Co. Inc. vs. AbbVie Inc. Jun 26 2017
The FDA Has Never Approved a Drug Like This in Its 111-Year History Jun 25 2017
Could Merck and Leap Union Be the One for Keytruda? Jun 24 2017
On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog Jun 23 2017
US stocks close mixed as Nasdaq ekes out gains Jun 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}